These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15125967)

  • 41. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
    Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
    Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
    [No Abstract]   [Full Text] [Related]  

  • 43. Inhibition of beef cortex membrane-bound 3', 5'-AMP phosphodiesterase by halogenated purines.
    Macdonald IA
    Pharmacol Res Commun; 1977 Jan; 9(1):49-58. PubMed ID: 194263
    [No Abstract]   [Full Text] [Related]  

  • 44. Structure/activity studies of flavonoids as inhibitors of cyclic AMP phosphodiesterase and relationship to quantum chemical indices.
    Ferrell JE; Chang Sing PD; Loew G; King R; Mansour JM; Mansour TE
    Mol Pharmacol; 1979 Sep; 16(2):556-68. PubMed ID: 229402
    [No Abstract]   [Full Text] [Related]  

  • 45. Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
    Chen CY
    Curr Opin Drug Discov Devel; 2005 Nov; 8(6):709-22. PubMed ID: 16312147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new phytotoxic nonenolide from Phoma herbarum.
    Rivero-Cruz JF; Macías M; Cerda-García-Rojas CM; Mata R
    J Nat Prod; 2003 Apr; 66(4):511-4. PubMed ID: 12713403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Searching for a reliable orientation of ligands in their binding site: comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors.
    Gratteri P; Bonaccini C; Melani F
    J Med Chem; 2005 Mar; 48(5):1657-65. PubMed ID: 15743207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.
    Sánchez AI; Meneses R; Mínguez JM; Núñez A; Castillo RR; Filace F; Burgos C; Vaquero JJ; Álvarez-Builla J; Cortés-Cabrera A; Gago F; Terricabras E; Segarra V
    Org Biomol Chem; 2014 Jun; 12(24):4233-42. PubMed ID: 24838636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives.
    Provins L; Christophe B; Danhaive P; Dulieu J; Gillard M; Quéré L; Stebbins K
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3077-80. PubMed ID: 17398090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
    Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
    J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 52. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-activity relationships of alkylxanthine inhibitors of phosphodiesterase IV isoenzyme.
    Yamamoto K; Sawanishi H; Miyamoto K
    Biol Pharm Bull; 1998 Apr; 21(4):356-9. PubMed ID: 9586572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Ogura K; Nagata N; Ueo N; Takahashi N; Sonoda Y; Kamei N
    Bioorg Med Chem Lett; 2015 Feb; 25(3):649-53. PubMed ID: 25529739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
    Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
    Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of cyclic AMP phosphodiesterases by cyclic nucleotide analogs and nitrogen heterocycles.
    Miller JP; Sigman CC; Johnson HL; Novinson T; Springer RH; Senga K; O'Brien DE; Robins RK
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():277-90. PubMed ID: 6326528
    [No Abstract]   [Full Text] [Related]  

  • 57. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
    Abbott BM; Thompson PE
    Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benzofuran based PDE4 inhibitors.
    McGarry DG; Regan JR; Volz FA; Hulme C; Moriarty KJ; Djuric SW; Souness JE; Miller BE; Travis JJ; Sweeney DM
    Bioorg Med Chem; 1999 Jun; 7(6):1131-9. PubMed ID: 10428384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A structure-activity relationship study on papaverine analogs.
    Gupta SP; Garg C; Gupta JK
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):265-8. PubMed ID: 2847262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.